Omeprazol Vir (Omeprazole)

Omeprazole, the active ingredient in Omeprazol Vir, is a proton pump inhibitor presented as an oral tablet for oral use. It reduces gastric acid production and is employed in the management of conditions such as gastro‑esophageal reflux disease, peptic ulcer disease, and for Helicobacter pylori eradication regimens.

GNH USA supplies Omeprazol Vir as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, adhering to stringent quality standards and regulatory requirements. The company ensures product integrity through controlled manufacturing processes and comprehensive documentation.

Omeprazole is a proton pump inhibitor used to manage acid‑related gastrointestinal disorders. - Gastro‑esophageal reflux disease (GERD): reduces reflux symptoms and promotes healing of esophageal irritation. - Peptic ulcer disease: facilitates ulcer healing by lowering gastric acidity. - Helicobacter pylori eradication regimens: enhances antibiotic effectiveness by suppressing acid production. - Erosive esophagitis: promotes mucosal healing and symptom relief.

Omeprazole may be associated with a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Headache: mild, transient headache that usually resolves without treatment. - Diarrhea: loose stools or increased frequency, often mild and self‑limiting. - Nausea: feeling of sickness or upset stomach, may improve with food. - Abdominal pain: mild discomfort or cramping in the stomach area. - Flatulence: increased gas production leading to bloating.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or difficulty breathing requiring immediate medical attention. - Clostridioides difficile infection: persistent watery diarrhea with abdominal pain, potentially serious. - Low magnesium levels: muscle cramps, irregular heartbeat, or seizures due to electrolyte imbalance. - Bone fractures: increased risk of hip, wrist, or spine fractures with prolonged therapy. - Acute interstitial nephritis: kidney inflammation presenting with fever, rash, and reduced urine output.

When prescribing omeprazole, clinicians should consider several precautionary measures to ensure safe use. - Assess renal function: dose adjustment may be needed in severe renal impairment. - Evaluate for infections: use may increase risk of gastrointestinal infections such as C. difficile. - Monitor long‑term therapy: prolonged use is associated with bone density loss and fractures. - Check electrolyte status: prolonged therapy can lead to hypomagnesemia; monitor levels periodically. - Review concomitant medications: potential interactions with drugs requiring acidic environment for absorption. - Store at ambient temperature: keep tablets in original packaging, protect from moisture and excessive heat.

Omeprazole can affect the plasma concentrations of several co‑administered medicines.

Major Interactions (Avoid): - Antiretrovirals (e.g., atazanavir, nelfinavir): reduced absorption leading to therapeutic failure. - Antifungal agents (e.g., itraconazole, ketoconazole): decreased bioavailability and loss of efficacy. - Clopidogrel: reduced conversion to active metabolite, diminishing antiplatelet effect.

Moderate Interactions (Monitor Closely): - Warfarin: possible increase in INR, requiring closer monitoring. - Digoxin: increased serum levels may occur, necessitating dosage adjustment. - Methotrexate: higher concentrations can develop, especially at high doses. - Diazepam: may experience increased sedation due to elevated levels.